Type 2 diabetes in latin America: recommendations on the flash glucose monitoring system

Krakauer M.; Gómez A.M.; Almeda-Valdes P.; Manrique H.; Ruiz Morosini M.L.; Godoy Jorquera G.; Nunes Salles J.E.; Sanhueza Costa D.; de Azeredo Siqueira R.; Faradji R.N.; Rincón Ramírez A.; Ré M.; Fériz Bonelo K.; Proietti A.; Lavalle-González F.J. · Diabetology and Metabolic Syndrome (2024) · DOI: 10.1186/s13098-024-01343-7

Resumen

Objective: To establish recommendations through the consensus of a Latin American experts panel on the use of the flash glucose monitoring system (fCGM) in people living with type 2 diabetes mellitus (T2DM) regarding the benefits and challenges of using the fCGM. Methods: An executive committee of experts was created, comprised by a panel of fifteen physicians, including endocrinologists and internal medicine physicians, with expertise in management of adult patients with T2DM. The experts were from various countries: Colombia, Chile, Peru, Mexico, Argentina, and Brazil. The modified Delphi method was used, considering a consensus level of at least 80% of the participants. A seventeen-item instrument was developed to establish recommendations on the use of fCGM in patients with T2DM in Latin American. Results: The number of glucose scans recommended per day with the fCGM for patients managed with oral antidiabetic drugs or basal insulin was a median of 6 scans per day, and for those managed with multiple insulin doses, a median of 10 scans per day was recommended. Additionally, a holistic and individualized management approach was recommended, taking into account new treatment directions and identifying patients who would benefit from the use of the fCGM. Conclusion: Continuous use of the fCGM is recommended for people living with T2DM, regardless of their type of treatment. These metrics must be evaluated individually for each patient profile. © The Author(s) 2024.